COVID-19 Presses the Accelerator on Biomedical R&D
December 9 at 6 am PT/ 9 am ET
COVID-19 has exposed many fault lines that FasterCures identifies as brakes on progress in biomedical R&D even in the best of times. The pandemic has offered a real-time, high-speed use case in how to accelerate the research and development of diagnostics, therapeutics, vaccines, and other products. What's more, it has inspired an unprecedented level of collaboration that has knocked down barriers and challenged orthodoxies. While the level of intensity may be unsustainable, there are lessons we can carry into the future to streamline how we develop and deliver the treatments and cures patients and society need.
Speakers
Amy Abernethy
Principal Deputy Commissioner and Acting Chief Information Officer, US Food and Drug Administration
Martin Landray
Professor of Medicine and Epidemiology, Nuffield Department of Population Health, University of Oxford
Pablo Legorreta
Founder and CEO, Royalty Pharma
Andrew Plump
President, Research and Development, Takeda Pharmaceuticals
Moderator
Annalisa Jenkins
Board Member, FasterCures, Milken Institute; Chair of the Court, The London School of Hygiene and Tropical Medicine